M
Mark M. Davis
Researcher at Stanford University
Publications - 623
Citations - 84251
Mark M. Davis is an academic researcher from Stanford University. The author has contributed to research in topics: T cell & T-cell receptor. The author has an hindex of 144, co-authored 581 publications receiving 74358 citations. Previous affiliations of Mark M. Davis include Washington University in St. Louis & University of Chicago.
Papers
More filters
Journal ArticleDOI
T-Cell Receptor (TCR) Clonotype-Specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T-Cell Clones Is Not Mediated by TCR Alone.
Nina C. Flerin,Huabiao Chen,Tynisha D. Glover,Pedro A. Lamothe,Pedro A. Lamothe,Jian Hua Zheng,Justin Fang,Zaza M. Ndhlovu,Evan W. Newell,Evan W. Newell,Mark M. Davis,Mark M. Davis,Bruce D. Walker,Bruce D. Walker,Harris Goldstein +14 more
TL;DR: The data suggest that the potent antiviral capacity of some HIV-specific CD8+ T cells is a consequence of factors in addition to TCR sequence that modulate functionality and contribute to the increased antiviral Capacity of HIV- specific CD8- T cells in elite controllers to inhibit HIV infection.
Journal ArticleDOI
Ataxia-telangiectasia-like disorder in a family deficient for MRE11A, caused by a MRE11 variant.
Maryam Sedghi,Mehri Salari,Ali-Reza Moslemi,Ariana Kariminejad,Mark M. Davis,Hayley Goullee,Björn Olsson,Nigel G. Laing,Homa Tajsharghi,Homa Tajsharghi +9 more
TL;DR: 3 siblings with the characteristic features of ataxia-telangiectasia-like disorder associated with a homozygous MRE11 synonymous variant causing nonsense-mediated mRNA decay (NMD) and Mre11A deficiency suffer from intellectual disability from early childhood.
Journal ArticleDOI
Cellular immunotherapy: antigen recognition is just the beginning
Daniel S. Chen,Mark M. Davis +1 more
TL;DR: Broad-scale immune monitoring, particularly high-throughput ex vivo analysis of human immune responses, promises to determine what comprises an effective immunotherapy and will lead to more sophisticated clinical trials, earlier determination of efficacy and individualized protocols.
Journal ArticleDOI
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor–Induced Myocarditis
Han-zhang Zhu,Francisco X Galdos,Daniel Lee,Sarah Waliany,Y. V. Huang,J J Ryan,Katherine Dang,Joel W. Neal,Heather A. Wakelee,Sunil Reddy,Sandy Srinivas,Lih-Ling Lin,Ronald M. Witteles,Holden T. Maecker,Mark M. Davis,Patricia K. Nguyen,Sean M. Wu +16 more
TL;DR: Clonal cytotoxic Temra CD8+ cells are significantly increased in the blood of patients with ICI myocarditis, corresponding to an analogous increase in effector cytot toxic CD8+, which may serve as attractive diagnostic/therapeutic targets for reducing life-threatening cardiac immune-related adverse events in ICI-treated patients with cancer.
Book ChapterDOI
The isolation of b and t cell-specific genes
TL;DR: The differences in gene expression between B and T cell lymphomas are measured and procedures for systematically isolating the genes which make up these differences are developed and a striking correlation between lineage relationships and gene expression is found.